Cwm LLC Purchases 130,200 Shares of Moderna, Inc. $MRNA

Cwm LLC grew its position in Moderna, Inc. (NASDAQ:MRNA) by 50.1% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 390,333 shares of the company’s stock after purchasing an additional 130,200 shares during the quarter. Cwm LLC owned approximately 0.10% of Moderna worth $10,082,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Rothschild Investment LLC lifted its holdings in Moderna by 94.1% in the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after buying an additional 446 shares during the period. TD Private Client Wealth LLC raised its position in shares of Moderna by 348.8% in the 2nd quarter. TD Private Client Wealth LLC now owns 956 shares of the company’s stock worth $26,000 after acquiring an additional 743 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new position in shares of Moderna in the 2nd quarter valued at about $26,000. Whittier Trust Co. bought a new stake in shares of Moderna during the 2nd quarter valued at about $28,000. Finally, MUFG Securities EMEA plc bought a new stake in shares of Moderna during the 2nd quarter valued at about $28,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $29.48, for a total value of $703,186.44. Following the transaction, the director owned 3,924 shares of the company’s stock, valued at approximately $115,679.52. This trade represents a 85.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 10.90% of the company’s stock.

Moderna Stock Down 4.7%

Shares of MRNA opened at $31.20 on Monday. The business’s fifty day moving average is $27.00 and its 200 day moving average is $27.39. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $48.92. The stock has a market cap of $12.19 billion, a P/E ratio of -3.87 and a beta of 1.11.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $1.64. The firm had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The business’s revenue was down 45.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.03 earnings per share. On average, analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on MRNA shares. Royal Bank Of Canada dropped their price target on Moderna from $28.00 to $25.00 and set a “sector perform” rating on the stock in a research note on Friday, November 21st. Barclays reduced their price objective on shares of Moderna from $31.00 to $25.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Moderna in a research report on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research note on Monday, December 1st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Monday, October 20th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Reduce” and a consensus price target of $29.21.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.